Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

239.93
+4.661.98%
Post-market: 239.930.00000.00%18:56 EDT
Volume:6.46M
Turnover:1.55B
Market Cap:578.06B
PE:21.75
High:241.46
Open:236.80
Low:235.73
Close:235.27
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.67
T/O Rate:0.27%
Dividend:5.14
Dividend Rate:2.14%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:7.09
PE(LYR):21.75

Loading ...

Johnson & Johnson Expands U.S. Footprint With More Than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

THOMSON REUTERS
·
Feb 18

J&J: Over $1 Bln Investment in Cell Therapy Manufacturing Facility in Montgomery County, Pennsylvania

THOMSON REUTERS
·
Feb 18

Daily disposable contact lenses set to power market rebound in 2026

Reuters
·
Feb 18

J&J Wins FDA Breakthrough Therapy Designation for RYBREVANT FASPRO in Advanced Head and Neck Cancer

Reuters
·
Feb 18

Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) Receives U.S. FDA Breakthrough Therapy Designation for Patients With Advanced Head and Neck Cancer

THOMSON REUTERS
·
Feb 18

J & J Snack Foods Shareholders Back Governance and Board

TIPRANKS
·
Feb 18

Talc Verdict And RYBREVANT Update Test Johnson & Johnson Valuation Story

Simply Wall St.
·
Feb 18

BRIEF-Trellus Health Extends Contract With Johnson & Johnson

Reuters
·
Feb 18

Trellus Health Plc - Collaboration With J&J Extended to Mid-2026 With Fixed Monthly Management Fee

THOMSON REUTERS
·
Feb 18

BRIEF-Ac Immune Says Informed Enrollment Has Been Temporarily Paused For Phase 2B Retain Trial

Reuters
·
Feb 18

AC Immune Sa: Informed by Janssen Pharmaceuticals That Enrollment Has Been Temporarily Paused for Phase 2B Retain Trial

THOMSON REUTERS
·
Feb 18

AC Immune Sa: Temporary Pause in Phase 2B Retain Trial Recruitment Is Voluntary & Not Related to New Safety Findings

THOMSON REUTERS
·
Feb 18

This auto-parts maker is jumping on the breakup bandwagon. Here's why the stock is tanking.

Dow Jones
·
Feb 18

Johnson & Johnson Says FDA Approved Monthly Dosing of Rybrevant Faspro for EGFR-Mutated Lung Cancer

MT Newswires Live
·
Feb 17

FDA Approves Monthly Dosing for Johnson & Johnson's RYBREVANT FASPRO

Reuters
·
Feb 17

FDA Approves Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) as the Only Egfr-Targeted Therapy That Can Be Administered Once a Month

THOMSON REUTERS
·
Feb 17

J&J: Monthly Dosing Reduces Treatment Visits While Maintaining Established Safety and Efficacy(1,2)

THOMSON REUTERS
·
Feb 17

Compass' psychedelic-based depression treatment scores second late-stage study win

Reuters
·
Feb 17

Why the 'HALO' trade boosting hard assets is no fluke, according to Morgan Stanley

Dow Jones
·
Feb 17

Medtronic beats quarterly profit estimates on robust demand for heart devices

Reuters
·
Feb 17